OBJECTIVES: The objective is to assess the budget impact of -iGlarLixi introduction in Algeria, in eligible population, over a time horizon of 5 years, from the Algerian health care system's perspective

METHODS: The budget impact analysis was designed with a 5-years time horizon for patients with T2DM, epidemiology data references were from National office of statistics, Stepwise WHO and IDMPS wave 7, the eligible population considered was: adults with T2DM insufficiently controlled on OAD with HbA1C >7 % , adults with T2DM insufficiently controlled on insulin with HbA1C >9%). The analysis included treatment costs in different treatment regimens, costs of glycemic self-monitoring which are covered by the social security (CNAS or CASNOS), administration costs (not including nurses costs). All costs were reported in Algerian dinars (AD). Deterministic sensitivity analysis was carried out on all relevant costs and parameters included in the budget impact assessment

RESULTS: The results showed a negative budget impact in the 1^st year: -262M AD. Starting from the 2^nd year the budget impact starts decreasing significatively and reaches: -475M AD, this is mainly driven by increasing market share of iGlarLixi, the negative impact reaches -1 Mds AD in the fifth year, this is due mainly that iGlarLixi take market share from basal bolus regimens and Premix bi-dialy and tri-daily resulting in cost savings as it is a less costly fixed-ratio combination. The cumulative budget over 5 years is (budget impact= -3 Mds AD).Sensitivity analyses determined that the cost of treatment and basal insulin dose had the potential to impact the base case analysis

CONCLUSIONS: The total budget for the introduction of iGlarLixi in Algeria has a considerable saving on health expenses and on the social security budget (-3Mds AD over 5 years). Therefore, iGlarLixi is a cost-saving alternative